TD Cowen analyst Joshua Jennings initiated coverage of Anteris Technologies (AVR) with a Buy rating and $15 price target Anteris has developed DurAVR, a first-in-class biomimetic transcatheter aortic valve replacement platform that has “disruptive potential,” the analyst tells investors in a research note. The firm says the hemodynamic outcomes generated in the clinical development program are differentiated and could drive Anteris to capture meaningful share in the $10B TAVR market in replicated in the next trial.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AVR:
- Anteris Technologies initiated with an Overweight at Cantor Fitzgerald
- Anteris Technologies initiated with an Overweight at Barclays
- Opening Day: ServiceTitan jumps 42% in trading debut
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
